SIZE XSSIZE SMSIZE MDSIZE LG

Practical Issues for Clinicians

Originally presented at HOPA's 14th Annual Conference, March 2018.

Managing Immune-Related Adverse Events with Immune Checkpoint Inhibitors

In this presentation we will review key concepts in the management of immunotherapy toxicities. We will use case-based examples to define common and uncommon toxicities of immunotherapy, review differences between single-agent and combination immunotherapy, and discuss management strategies for immunotherapy toxicities. The target audience is pharmacists working in clinical practice.

Speaker

Christopher Campen, PharmD BCOP

Overcoming the Blood-Brain Barrier: New Opportunities for Treatment of Brain Metastases in Non-Small-Cell Lung Cancer

Lung cancer is the leading cause of death in the United States, and brain metastases are a frequent complication of NSCLC, with about 25%–40% of patients developing brain metastases. Many first-generation tyrosine kinase inhibitors (TKIs) for treatment of epidermal growth factor receptor (EGFR)– and anaplastic lymphoma kinase (ALK)–mutant lung cancers have poor blood-brain barrier penetration, allowing the central nervous system (CNS) to serve as a sanctuary site of disease. With advances in treatment, many second- and third- generation TKIs, such as osimertinib, alectinib, and brigatinib, have increased blood-brain barrier permeability and have been shown effective in controlling and treating CNS metastases. This presentation will review the pathophysiology of the blood-brain barrier and mechanisms of permeation of oncologic agents to cross the blood-brain barrier; compare EGFR TKIs’ and ALK TKIs’ pharmacokinetics, cerebrospinal fluid penetration, and safety profile; and provide evidence-based literature on TKIs’ intracranial efficacy.

Speaker

Samantha N. Reiss, PharmD BCOP

Activity type

Patient Management & Therapeutics

Accreditation Statement

logo acpe

The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. ACPE credit must be claimed by March 22, 2021.

This activity has been approved for .1 CEU

This course is also included as part of the Best of 2018 Annual Conference Recordings Bundle.

Release Date: September 26, 2018

Expiration Date: March 22, 2021

Member: $25

Non-Member: $35

Purchase Now

xs
sm
md
lg